Market Research Report Diabetes & Obesity Drug Development PipelineReview

Diabetes & Obesity Drug Development Pipeline
Review and Market Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report,
titled “Diabetes & Obesity Drug Development Pipeline Review, 2016” to its report
offerings. The report understand the overall pipeline, with an at-a-glance overview
of all products in therapeutic development for each indication. Analyze the
companies, institutions and universities currently operating in the pipeline, and the
products being fielded by each of these.
Request for Sample Report:
http://www.marketresearchhub.com/enquiry.php?type=S&repid=877732
The diabetes and obesity disease cluster is currently dominated by therapeutics
indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM),
and the majority of the pipeline, in terms of both quantity and quality of products, is
attributable to these indications. While products indicated for obesity do not
currently have a large market presence, there are a large number of these products
in the pipeline, with the majority in early stages of development.
The combined therapy area of diabetes and obesity presents a strong pipeline,
accounting for a large proportion of the overall metabolic disorders therapy area.
The majority of products are small molecules and biologics, which reflects the
overall pharmacotherapeutic market trend.
An increasing pipeline presence for obesity-indicated products and overwhelming
global media interest highlight the relevance of this indication and its future potential
global revenues. However, the number of pharmacotherapeutic products for obesity
is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor